临床试验 以下为当前的临床试验。500 研究 肿瘤科(内科) (仅限仍在招募的研究). 按院区、状态和其他条件筛选该研究列表。 A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. This study consists of two parts to explore BGB-16673 recommended dosing: a part 1 monotherapy dose finding and a part 2 (cohort expansion in two cohorts). A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Jacksonville, Fla. The purpose of this study is to assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575. Cutaneous Lymphoma Database Scottsdale/Phoenix, Ariz. The purpose of this study is to create a long-term, prospective database of cutaneous lymphoma that will lead to a better understanding of the biological behavior of cutaneous lymphomas as well as the effectiveness of interventions. Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men Jacksonville, Fla. The objective of this pilot stdy is to plan, develop and establish the acceptance and usability of a Point of Prostate Cancer Diagnosis (PPCD) iCCaRE Virtual Robot Assistant (ViRA). The specific aims of this study are to plan and develop a PPCD iCCaRE ViRA model that will provide social determinants of health (SDOH) navigation services, psycho-oncology support and emotional support using qualitative formative research, and to establish the acceptance and usability of the iCCaRE ViRA at a urology clinic among 50 Black men (BM). A Study to Identify Late-Occurring Complications in Childhood Cancer Survivors Rochester, Minn. The purpose of this trial is to identify cancer survivors who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. Ado-trastuzumab emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients Rochester, Minn. The purpose of this study is to prospectively evaluate the patient-reported outcomes data of T-DM1 induced peripheral neuropathy like prior research focused on paclitaxel-, paclitaxel/CBDCA-, oxaliplatin-, and cisplatin-induced peripheral neuropathy, to better understand the similarities and differences of chemotherapy-induced peripheral neuropathy (CIPN) symptoms caused by different agents, their pathogenesis, and impacts. Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cell (CAR T) in BAFFR-expressing B-cell Hematologic Malignancies and Autoimmune Rheumatologic Disorders Jacksonville, Fla. The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies including large B-cell, mantle cell and follicular lymphoma, chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. A Study of HFB200301 in Adult Patients With Advanced Solid Tumors Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to test the safety and tolerability of HFB200301 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable dose of HFB200301 is determined. During the expansion part, participants will take the dose of study drug that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have. A Study to Evaluate Remote Monitoring in Cancer Care Rochester, Minn. The objectives of this study are to establish the validity for the use of wearable device for continuous, remote monitoring of physiologic parameters, to establish the validity for the use of wearable device for continuous, remote monitoring of physiologic parameters, and to develop patient-specific algorithms to predict the trajectory of CRS and or neurotoxicity and time to escalation of medical intervention is needed. A Study to Evaluate Chemotherapy-Induced Nausea in Breast Cancer Patients Rochester, Minn., Mankato, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz., Albert Lea, Minn. The long-term goal of this study is to alleviate the occurrence of CIN and fatigue and to improve chemotherapy treatment outcomes. The identification of associations between fatigue, CIN and chemotherapy-induced changes in gut microbiome composition profiles will increase our understanding of these mechanisms that underlie patient symptom experience. An increased understanding of the underlying mechanisms will provide targets for the development of novel interventions to help alleviate fatigue and CIN. Pagination 临床研究 PrevPrevious Page Go to page 22 Go to page 33 Go to page 44 Go to page 55 Go to page 66 NextNext Page 申请预约 专长与排名研究 May 09, 2023 妙佑医疗国际明尼苏达州罗切斯特院区、妙佑医疗国际佛罗里达州杰克逊维尔院区和妙佑医疗国际亚利桑那州凤凰城/斯科茨代尔院区均在《美国新闻与世界报道》2024-2025 全美最佳癌症医院评选中名列前茅。 了解更多关于这一最高荣誉的信息 肿瘤科(内科)科室首页部分概述主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 研究完全以患者为中心。 请参见副本 供视频使用 研究完全以患者为中心。 [音乐播放] 妙佑医疗国际神经学教授 Joseph Sirven 医学博士:妙佑医疗的使命以患者为中心。患者第一。我们的使命和研究是为了更好地帮助患者,提供以患者为中心的护理。在很多方面,这是一个循环。这个过程可能很简单,就是先在实验室里出现一个想法,然后带到病床旁加以实施,如果一切顺利,对患者有所助益, 就形成标准。我认为这就是妙佑医疗国际研究方法的一个独特之处,而这种以患者为中心的方式,也是妙佑医疗在众多医疗机构中脱颖而出的原因之一。 部分预约门诊概述主治医生专业团队专长与排名临床试验研究患者故事费用与保险Mayo Clinic 新闻转诊 ORG-20180179 医学科室与中心 肿瘤科(内科)